You are viewing the site in preview mode
Skip to main content
| Variable (N of trials with reported variable) | N (%)a |
|---|
| Clinical trial registry (N = 927) |
| Chinese Clinical Trials Registry (ChiCTR) | 581 (63) |
| ClinicalTrials.gov | 286 (30) |
| EU Clinical Trials Register | 21 (2.2) |
| Australian New Zealand Clinical Trials Registry (ANZCTR) | 9 (1) |
| ISRCTN | 8 (0.9) |
| IRCT | 8 (0.9) |
| Other | 14 (1.5) |
| Recruitment status (N = 915) |
| Not recruiting | 453 (50) |
| Recruiting | 441 (48) |
| Authorized | 21 (2.2) |
| Minimal age of participants (N = 744) |
| 18 years | 532 (72) |
| 0 years | 26 (3.5) |
| 14 years | 18 (2.4) |
| 16 years | 15 (2) |
| 1 year | 13 (1.7) |
| Other | 140 (15) |
| Maximal age of participants (N = 663) |
| Not applicable/no upper limit | 197 (30) |
| 80 years | 59 (9) |
| 75 years | 55 (8.2) |
| 90 years | 42 (6.3) |
| 65 years | 32 (4.8) |
| Other | 278 (42) |
| Eligibility of participants based on sex (N = 921) |
| Both men and women | 892 (97) |
| Only men | 18 (1.9) |
| Only women | 11 (1.2) |
| Self-reported study type (N = 927) |
| Interventional | 535 (58) |
| Observational | 303 (33) |
| Diagnostic test | 35 (3.8) |
| Observational (patient registry) | 19 (2) |
| Epidemiological research | 10 (1) |
| Other | 25 (2.7) |
| Location of trials located in single countries (N = 825) |
| China | 622 (63) |
| United States | 33 (4.0) |
| France | 21 (2.5) |
| Italy | 17 (2.1) |
| United Kingdom | 10 (1.2) |
| Other | 122 (15) |
| Tested interventions (N = 535) |
| Hydroxychloroquine | 39 (7.2) |
| Chloroquine | 16 (3.0) |
| Tocilizumab | 10 (1.9) |
| Lopinavir/ritonavir combination | 10 (1.9) |
| Convalescent plasma | 9 (1.7) |
| Other | 451 (84) |
- aDenominator is provided in the first column, as “N of trials with reported variable”; for some variables due to rounding the sums may not be exact 100%, for variables we presented only five most frequent categories
